Cosibelimab
Medication From Wikipedia, the free encyclopedia
Cosibelimab, sold under the brand name Unloxcyt, is a monoclonal antibody used for the treatment of cutaneous squamous-cell carcinoma.[1] It is a human immunoglobulin G1 (IgG1) programmed death ligand-1 (PD-L1) blocking antibody.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | PD-L1 |
| Clinical data | |
| Trade names | Unloxcyt |
| Other names | CK-301, TG-1501, cosibelimab-ipdl |
| License data |
|
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6388H9912N1716O2032S44 |
| Molar mass | 144674.18 g·mol−1 |
The most common adverse reactions include fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritis, edema, localized infection, and urinary tract infection.[3]
Cosibelimab was approved for medical use in the United States in December 2024.[1][3][4][5]
Medical uses
Cosibelimab is indicated for the treatment of adults with metastatic cutaneous squamous-cell carcinoma or locally advanced cutaneous squamous-cell carcinoma who are not candidates for curative surgery or curative radiation.[1][3]
History
Efficacy was evaluated in study CK-301-101 (NCT03212404), a multicenter, multicohort, open-label trial in 109 participants with metastatic cutaneous squamous-cell carcinoma or locally advanced cutaneous squamous-cell carcinoma who were not candidates for curative surgery or curative radiation.[3] Participants were excluded if they had any of the following: active or suspected autoimmune disease, allogeneic transplant within six months prior to treatment, prior treatment with anti-PD-1/PD-L1 blocking antibodies or other immune checkpoint inhibitor therapy, uncontrolled or significant cardiovascular disease, ECOG PS • 2, or infection with HIV, hepatitis B, or hepatitis C.[3]
Society and culture
Legal status
Cosibelimab was approved for medical use in the United States in December 2024.[3][6]
Names
Cosibelimab is the international nonproprietary name.[7]
Cosibelimab is sold under the brand name Unloxcyt.[1]
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.